

*Acta Endocrinologica*

acta  
endocrino  
logica

# acta endocrino logica

Volume 91

May – August 1979

Copenhagen

CHIEF EDITOR J. STARUP . DENMARK

LOCAL EDITORS C. BINDER . DENMARK

J.-F. DYMLING . SWEDEN

T. B. van WIMERSMA GREIDANUS . THE NETHERLANDS

B.-A. LAMBERG . FINLAND

J. MÜLLER . SWITZERLAND

N. NORMAN . NORWAY

J. TAMM . FEDERAL REPUBLIC OF GERMANY

CONSULTING EDITORS R. BORTH . CANADA

C. HAMBURGER . DENMARK

Advisory Panel, page V  
Contents Vol. 91, page VII  
Authors' Index, page XIII  
Subject Index, page XVII



179: 10

Printed in Denmark  
by Bogtrykkeriet Forum  
Copenhagen

**PITUITARY**

*Aono T., Miyake A., Shioji T., Yasuda M., Koike K. & Kurachi K.*: Restoration of oestrogen positive feedback effect on LH release by bromocriptine in hyperprolactinaemic patients with galactorrhoea-amenorrhoea ..... 591

*Barbarino A., de Marinis L., Menini E., Anile C. & Maira G.*: Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery ..... 397

*Bergquist C., Nillius S. J., Bergh T., Skarin G. & Wide L.*: Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue .... 601

*Carmina E., Lo Coco R., Lanzama P. & Janni A.*: Effect of the acute administration of haloperidol and pimozide on plasma GH levels in acromegaly ..... 609

*Dickerman Z., Prager-Lewin R. & Laron Z.*: The plasma FSH and LH response to synthetic LH-RH in normal pre-pubertal and early pubertal girls - a re-evaluation ..... 14

*Favre L., Rogers L. M., Cobb C. A. & Rabin D.*: Gigantism associated with a pituitary tumour secreting growth hormone and prolactin and cured by transsphenoidal hypophysectomy ..... 193

*Goncharov N., Antonichev A. V., Gortuschkin V. M., Chachundocova L., Robertson D. M. & Diczfalusy E.*: Luteinizing hormone levels during the menstrual cycle of the baboon (*Papio hamadryas*) ..... 49

*Hagino N., Nakamoto O., Kunz Y., Arimura A., Coy D. H. & Schally A. V.*: Effect of D-Trp6-LH-RH on the pituitary-gonadal axis during the luteal phase in the baboon ..... 217

*Hanker J. P., Schellong G. & Schneider H. P. G.*: The functional state of the hypothalamopituitary axis after high-dose oestrogen therapy in excessively tall girls ..... 19

*Jeppsson S., Larsson I. & Thorell J. I.*: Characterization of specific antisera to native human luteinizing hormone ..... 238

*Jeske W.*: The effect of metoclopramide, TRH and L-DOPA on prolactin secretion in pituitary adenoma and in 'functional' galactorrhoea syndrome ..... 385

*Kawakami M. & Higuchi T.*: Effects of active and passive immunization with LH-RH on gonadotrophin secretion and reproductive function in female rats ..... 616

*Lincoln G. A.*: Light-induced rhythms of prolactin secretion in the ram and the effect of cranial sympathectomy ..... 421

*Martin L. G., Grossman M. S., Connor T. B., Levitsky L. L., Clark J. W. & Camitta F. D.*: Effect of androgen on growth hormone secretion and growth in boys with short stature ..... 201

*Miyke A., Aono T., Tanizawa O., Kurachi H. & Kurachi K.*: Restoration of the gonadotrophin response to LH-RH and oestrogen administration in patients after molar abortion ..... 30

<i>Peters F., Lummerich M. &amp; Breckwoldt M.</i> : Inhibition of prolactin and lactation by methylergometrine hydrogenmaleate .....	213
<i>Pinto H., Wajchenberg B. L., Lima F. B., Goldman J., Comaru-Schally A. M. &amp; Schally A. V.</i> : Evaluation of the gonadotrophic responsiveness of the pituitary to acute and prolonged administration of LH/FSH-releasing hormone (LH-RH) in normal females and males .....	1
<i>Pontiroli A. E., Gala R. R., Pellicciotta G., De Pasqua A., Girardi A. M. &amp; Pozza G.</i> : Study on the reproducibility of human prolactin response to sulpiride, benserazide, insulin hypoglycaemia and arginine infusion .....	410
<i>Spencer E. M., Uthne K. O. &amp; Arnold W. C.</i> : Growth impairment with elevated somatomedin levels in children with chronic renal insufficiency .....	36
<i>Traklrungrsi C., Reiter R. J., Traklrungrsi W. K., Vaughan M. K. &amp; Waring-Ellis P. J.</i> : Interaction of daily injections and subcutaneous reservoirs of melatonin on the reproductive physiology of female Syrian hamsters .....	59
<i>Van Damme M.-P., Robertson D. M., Marana R., Ritzén E. M. &amp; Diczfalusy E.</i> : A sensitive and specific in vitro bioassay method for the measurement of follicle-stimulating hormone activity .....	224
<i>Vierhapper H., Waldhäusl W. &amp; Nowotny P.</i> : Gonadotrophin-release upon iv-administration of a long-acting analogue of luteinizing hormone-releasing hormone in females with increased plasma-androgens .....	577
<i>Wakabayashi I., Kanda M., Miki N., Demura R. &amp; Shizume K.</i> : Chlorpromazine inhibits episodic growth hormone secretion in the rat .....	428

## THYROID

<i>Bratusch-Marrain P., Haydl H., Waldhäusl W., Dudczak R. &amp; Graninger W.</i> : Familial thyroxine-binding globulin deficiency in association with non-toxic goitre .....	70
<i>Feldt-Rasmussen U., Bech K. &amp; Date J.</i> : Serum thyroglobulin in patients with toxic and non-toxic goitres compared to sex- and age-matched control subjects .....	264
<i>Fragu P., Ben Othman S. &amp; Nataf B. M.</i> : Effect of PTU added to a low iodine diet on peroxidase activity and other parameters of thyroid function in rats .....	462
<i>Hendriks J. Th. A. M. &amp; Smeenk D.</i> : Investigation of bone and mineral metabolism in hyperthyroidism before and after treatment using calcitonin, <sup>47</sup> Ca and balance studies .....	77
<i>Lamberg B.-A., Rantanen M., Saarinen P., Liewendahi K. &amp; Sivula A.</i> : Suppression of the TSH response to TRH by thyroxine therapy in differentiated thyroid carcinoma patients .....	248
<i>Linde J. &amp; Friis Th.</i> : Osteoporosis in hyperthyroidism estimated by photon absorptiometry .....	437
<i>Myhre L. &amp; Gautvik K. M.</i> : The use of region specific radioimmunoassays for characterization of circulating calcitonin in patients with medullary carcinoma of the thyroid gland .....	449
<i>Männistö P. T. &amp; Leppäluoto J.</i> : Effects of methylmercaptoimidazole (MMI), propylthiouracil (PTU) potassium perchlorate (KClO <sub>4</sub> ) and potassium iodide (KI) on the serum concentrations of thyrotrophin (TSH) and thyroid hormones in the rat .....	271
<i>Ochi Y., Hosoda S., Hachiya T., Yoshimura M., Miyazaki T. &amp; Kajita Y.</i> : Studies on a receptor assay for an antibody to human thyroid plasma membrane .....	89

<i>Scriba P. C., Bauer M., Emmert D., Fateh-Moghadam A., Hofmann G. G., Horn K. &amp; Pickardt C. R.</i> : Effects of obesity, total fasting and re-alimentation on L-thyroxine (T <sub>4</sub> ), 3,5,3'-L-triiodothyronine (T <sub>3</sub> ), 3,3,5'-L-triiodothyronine (rT <sub>3</sub> ), thyroxine binding globulin (TBG), cortisol, thyrotrophin, cortisol binding globulin (CBG), transferrin, α <sub>2</sub> -haptoglobin and complement C'3 in serum . . . . .	629
<i>Smeds S. &amp; Anderberg B.</i> : Depletion of colloid 27S and larger thyroid iodoproteins following treatment with propylthiouracil . . . . .	644
<i>Sugenoya A., Silverberg J., Trokoudes K., Row V. V. &amp; Volpé R.</i> : Macrophage-lymphocyte interaction in Graves' disease and Hashimoto's thyroiditis . . . . .	99
<i>van Hardeveld C., Zuidwijk M. J. &amp; Kassenaar A. A. H.</i> : Studies on the origin of altered thyroid hormone levels in the blood of rats during cold exposure I. . . . .	473
<i>van Hardeveld C., Zuidwijk M. J. &amp; kassenaar A. A. H.</i> : Studies on the origin of altered thyroid hormone levels in the blood of rats during cold exposure II. . . . .	484
<i>Zanoboni A., Zanoboni-Muciaccia W. &amp; Zanussi C.</i> : Enhanced TSH stimulating effect of sulpiride in man . . . . .	257

## PANCREAS

<i>Cerasi E., Efendic S., Thornqvist C. &amp; Luft R.</i> : Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects . .	282
<i>Schäfer R. &amp; Schatz H.</i> : Stimulation of (pro-)insulin biosynthesis and release by gastric inhibitory polypeptide in isolated islets of rat pancreas . . . . .	493

## ADRENALS

<i>Birkhäuser M., Riondel A. &amp; Vallotton M. B.</i> : Bromocriptine-induced modulation of plasma aldosterone response to acute stimulations . . . . .	294
<i>Cavagnini F., Di Landro A., Maraschini C., Invitti C. &amp; Pinto M. L.</i> : Effect of two prostaglandin synthesis inhibitors, indomethacin and acetylsalicylic acid, on plasma ACTH and cortisol levels in man . . . . .	666
<i>Deck K. A., Baur P. &amp; Hillen H.</i> : Plasma clearance of cortisol as a function of plasma cortisol levels in normal and obese persons and in patients with uraemia or cirrhosis of the liver . . . . .	122
<i>Faber J., Cohn D., Kirkegaard C., Christy M., Siersbæk-Nielsen K., Friis T. &amp; Nerup J.</i> : Subclinical hypothyroidism in Addison's disease . . . . .	674
<i>Faulborn K. W., Fenske M., Pitzel L. &amp; König A.</i> : Effects of an intravenous injection of tetracosactid on plasma corticosteroid and testosterone levels in unstressed male rabbits . . . . .	511
<i>Kahri A. I., Voutilainen R. &amp; Salmenperä M.</i> : Different biological action of corticosteroids, corticosterone and cortisol, as a base of zonal function of adrenal cortex	329
<i>Kelly W. F., Barnes A. J., Cassar J., White M., Mashiter K., Loizou S., Welbourn R. B. &amp; Joplin G. F.</i> : Cushing's syndrome due to adrenocortical carcinoma – a comprehensive clinical and biochemical study of patients treated by surgery and chemotherapy . . . . .	303
<i>Kraiem Z., Rosenthal T., Rotzak R. &amp; Lunenfeld B.</i> : Angiotensin II and K challenge following prolonged ACTH administration to normal subjects . . . . .	657
<i>Krølner B., Larsen S. &amp; Damkjær Nielsen M.</i> : Corticosterone secreting adrenal carcinoma and empty sella turcica: a case report . . . . .	650

<i>McKenna T. J., Lorber D., Lacroix A. &amp; Rabin D.</i> : Testicular activity in Cushing's disease .....	501
<i>Nielsen J.</i> : Poly-maleic acid anhydride (PMA) coupled cortisol antibody in routine determination of urinary free cortisol .....	680
<i>Ottenweller J. E., Meier A. H., Russo A. C. &amp; Frenzke M. E.</i> : Circadian rhythms of plasma corticosterone binding activity in the rat and the mouse .....	150
<i>Robinson P. M., Rowe E. J. &amp; Wintour E. M.</i> : The histogenesis of the adrenal cortex in the foetal sheep .....	134
<i>Weil J., Bidlingmaier F., Sippell W. G., Butenandt O. &amp; Knorr D.</i> : Comparison of two tests for heterozygosity in congenital adrenal hyperplasia (CAH) .....	109
<i>Yoshida K., Satowa H., Sato A., Ichikawa Y., Kream J., Levin J., Zumoff B., Hellman L. &amp; Fukushima D. K.</i> : Plasma cortisol profiles in Cushing's syndrome .....	319

## OVARIES

<i>Borth R., Benoit H. J. &amp; Woolever C. A.</i> : Transducer probe for the measurement of oestradiol-induced changes in the vagina of ovariectomized ewes .....	167
<i>Emons G., Ball P., v. Postel G. &amp; Knuppen R.</i> : Radioimmunoassay for 2-methoxyoestrone in human plasma .....	158
<i>Lucky A. W., Marynick S. P., Rebar R. W., Cutler G. B., Glen M., Johnsonbaugh R. E. &amp; Loriaux D. L.</i> : Replacement oral ethinyloestradiol therapy for gonadal dysgenesis: growth and adrenal androgen studies .....	519
<i>Rao Ch. V., Estergreen V. L., Carman, Jr. F. R. &amp; Moss G. E.</i> : Receptors for gonadotrophin and prostaglandin $F_{2\alpha}$ in bovine corpora lutea of early, mid and late luteal phase .....	529

## PREGNANCY

<i>Dattatreyamurty B., Sheth A. R., Purandare T. V., Companiwalla R. &amp; Krishna U.</i> : Gonadotrophins during second trimester of pregnancy. I. LH and hCG levels in maternal serum and amniotic fluid and their relationship to the sex of the foetus .....	692
<i>Dawood M. Y., Lauersen N. H., Trivedi D., Ylikorkala O. &amp; Fuchs F.</i> : Studies on oxytocin in the baboon during pregnancy and delivery .....	704
<i>Odink J., Brand E. C. &amp; Van Hall E. V.</i> : A pitfall in the ovarian ascorbic acid depletion assay (OAAD): effect of unilateral ovariectomy, hCG and asialo-hCG .....	538

## TESTES

<i>de Lange W. E., Snoep M. C. &amp; Doorenbos H.</i> : The effect of short-term testosterone treatment in boys with delayed puberty .....	177
<i>Føgh M., Corker C. S., Hunter W. M., McLean H., Philip J., Schou G. &amp; Skakkebaek N. E.</i> : The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men .....	545

<i>Kley H. K., Solbach H. G., McKinman J. C. &amp; Krüskemper H. L.</i> : Testosterone decrease and oestrogen increase in male patients with obesity .....	553
<i>Lacroix A. &amp; Pelletier J.</i> : LH and testosterone release in developing bulls following LH-RH treatment. Effect of gonadectomy and chronic testosterone propionate pre-treatment .....	719

## MISCELLANEOUS

<i>Boris A., Hurley J. F., Trmal T., Mallon J. P. &amp; Matuszewski D. S.</i> : Inhibition of diphosphonate-blocked bone mineralization. Evidence that calcitonin promotes mineralization .....	351
<i>Christensen C. K., Nielsen H. E., Kamstrup O., Olsen K. J., Brandsborg M. &amp; Brandsborg O.</i> : Serum gastrin and serum calcitonin in patients with chronic renal failure .....	564
<i>Dionne F. T., Dubé J. Y., Lesage R. L. &amp; Tremblay R. R.</i> : <i>In vivo</i> androgen binding in rat skeletal and perineal muscles .....	362
<i>Elo H. A.</i> : Comparison of avidin induction in the differentiated and undifferentiated chick oviduct by progesterone, actinomycin D and oviductal injury .....	743
<i>Lerner U. &amp; Gustafson G. T.</i> : Inhibitory effect of dibutyryl cyclic AMP on release of calcium, inorganic phosphate and lysosomal enzymes from calvarial bones cultured for 24 hours .....	730
<i>Lund Bj., Lund B. &amp; Sørensen O. H.</i> : Measurement of circulating 1,25-dihydroxy-vitamin D in man. Changes in serum concentrations during treatment with 1 $\alpha$ -hydroxycholecalciferol .....	338
<i>Sartin J. L., Bruot B. C. &amp; Orts R. J.</i> : Neurotransmitter regulation of arginine vasotocin release from rat pineal glands <i>in vitro</i> .....	571
<i>Tunn U., Senge Th., Schenck B. &amp; Neumann F.</i> : Biochemical and histological studies on prostates in castrated dogs after treatment with androstenediol, oestradiol and cyproterone acetate .....	373
<i>Valdés E., Fernández del Castillo C., Gutiérrez R., Larrea F., Medina M. &amp; Pérez-Palacios G.</i> : Endocrine studies and successful treatment in a patient with true hermaphroditism .....	184

---

Medizinische Klinik Innenstadt and Institut für Klinische Chemie,  
Universität München, D-8000 München, FRG

EFFECTS OF OBESITY, TOTAL FASTING AND RE-ALIMENTATION  
ON L-THYROXINE ( $T_4$ ), 3,5,3'-L-TRIIODOTHYRONINE ( $T_3$ ),  
3,3',5'-L-TRIIODOTHYRONINE ( $rT_3$ ), THYROXINE BINDING  
GLOBULIN (TBG), CORTISOL, THYROTROPHIN, CORTISOL BINDING  
GLOBULIN (CBG), TRANSFERRIN,  $\alpha_2$ -HAPTOGLOBIN AND  
COMPLEMENT C'3 IN SERUM

By

*Peter C. Scriba<sup>1)</sup>, Manfred Bauer, Dieter Emmert, Ahmed Fateh-Moghadam,  
Gert G. Hofmann, Klaus Horn and C. Renate Pickardt*

ABSTRACT

The effects of total fasting for  $31 \pm 10$  days followed by re-alimentation with an 800 calorie diet on thyroid function, i.e.  $T_4$ ,  $T_3$ ,  $rT_3$ ,  $RT_3U$  (resin  $T_3$  uptake), and TSH, and on TBG levels in serum were studied sequentially in obese hospitalized patients ( $N = 18$ ). Additionally, cortisol, growth hormone, prolactin, parathyrin and free fatty acids were followed as hormonal and metabolic parameters, respectively. Further, CBG, transferrin,  $\alpha_2$ -haptoglobin and complement C'3 were measured as representatives of other serum proteins.

Results before fasting:  $T_4$ ,  $T_3$ , TBG, cortisol, CBG,  $\alpha_2$ -haptoglobin and complement C'3 of the obese patients were elevated when compared with healthy normal weight controls, whereas  $rT_3$ ,  $T_4$ /TBG ratio,  $T_3$ /TBG ratio, TSH, cortisol/CBG ratio, growth hormone, prolactin, parathyrin and transferrin of the obese group were normal.  $RT_3U$  and  $fT_4$  index were decreased in the obese patients.

Results during fasting: Significant decreases were observed during fasting for the following parameters -  $T_3$ , TBG,  $T_3$ /TBG ratio, transferrin,  $\alpha_2$ -

---

<sup>1)</sup> A preliminary report was presented at the XI. Acta Endocrinologica Congress, Lausanne, Switzerland (*Scriba et al.* 1977).

haptoglobin, complement C'3,  $rT_3$ ,  $T_4$ /TBG ratio,  $RT_3U$ ,  $fT_4$  index and FFA increased.  $T_4$ , TSH response to TRH stimulation, cortisol, CBG, cortisol/CBG ratio, parathyrin, growth hormone and prolactin did not change.

Results during re-alimentation:  $T_3$ , TBG,  $T_3$ /TBG ratio, TSH response to TRH, transferrin,  $\alpha_2$ -haptoglobin and complement C'3 increased. Conversely,  $rT_3$ ,  $RT_3U$ , FFA, cortisol and cortisol/CBG ratio decreased, whereas the other parameters did not change.

Conclusions: 1) There is no evidence for primary hypothyroidism in obese patients during prolonged fasting and re-alimentation. 2) The rapid decrease of  $T_3$  and increase of  $RT_3U$  after initiation of fasting are not fully explained by the observed slower decreases in TBG. 3) The alterations of  $T_3$ ,  $rT_3$  and  $RT_3U$  resemble in their kinetics the changes in FFA levels. 4) Fasting reduced the levels of only certain serum proteins, interestingly TBG, transferrin,  $\alpha_2$ -haptoglobin and complement C'3, all of which, except transferrin, are elevated in obesity. 5) The magnitude of the observed decreases does not suggest any clinically relevant deficiencies in serum proteins. 6) Re-alimentation reverses rapidly all observed changes.

Several recent publications have dealt with alterations of thyroid hormone metabolism in obese patients during total fasting. 3,5,3'-L-triiodothyronine ( $T_3$ ) levels in serum were shown to decrease during fasting whereas the metabolically inactive metabolite of thyroxine 3,3',5'-L-triiodothyronine (reverse  $T_3$ ,  $rT_3$ ) increased (Balsam & Ingbar 1977; Carlson *et al.* 1977; Croxson *et al.* 1977; Merimee & Fineberg 1976; Palmblad *et al.* 1977; Portnay *et al.* 1974; Vagenakis *et al.* 1975, 1977) while total thyroxine ( $T_4$ ) levels remained constant. The daily weight loss decreased during several weeks of total fasting and the basal metabolic rate (BMR) also diminished with the duration of the fasting (Ditschuneit 1976). This study was performed in order to evaluate the possibility that the changes in BMR could be due to thyroid hormone deficiency arising from fasting (Hofmann *et al.* 1974; Scriba *et al.* 1967; Scriba & Hofmann 1976).

The total thyroid hormone concentration in serum depends on the concentration of their specific transport proteins of which thyroxine binding globulin (TBG) is the most important. For this study, it had to be taken into consideration that the serum globulins transferrin,  $\alpha_2$ -haptoglobin and complement C'3 ( $\beta_1A$ -globulin) decreased during total fasting of 3 weeks duration (Fateh-Moghadam *et al.* 1977). The alterations of the TBG levels during fasting and re-alimentation had therefore to be studied for a better understanding of the thyroid function of obese patients during this procedure, also in view of the fact that an abnormally high binding of thyroid hormones to serum proteins has been reported in earlier studies (Premachandra *et al.* 1970; Schatz *et al.* 1967; Scriba *et al.* 1967).

## METHODS

### *Patients*

Treatment of alimentary obesity by total fasting of maximally 50 days duration was performed on 18 hospitalized patients, in whom other metabolic or endocrine diseases and liver or kidney diseases, respectively, had been excluded. The patients received an 800 calorie (3336 kJ) mixed diet for subsequent re-alimentation. Patients admitted to this study had no recent treatment with metabolically active drugs, in particular laxatives, diuretics, thyroid hormones or corticosteroids. In the female patients, no hormonal contraception had been practised for at least 4 weeks prior to the initiation of the fasting. The mean age of the patients was 27 years, 9 males were from 15 to 39 years old, 9 females from 16 to 46 years. The mean initial weight was  $168.5 \pm 20.5\%$  (SD) of the ideal weight in females and  $166.4 \pm 20.2\%$  in males.

### *Fasting*

The mean duration of the fasting was  $31 \pm 10$  days, the daily weight loss was  $454 \pm 96$  g/day in females and  $547 \pm 137$  g/day in males. The following determinations were performed for control of the fasting and as a precaution against complications: Free fatty acids, calcium, potassium, sodium and uric acid in serum, acetone in urine and electrocardiogram at least weekly. The transaminases were controlled fortnightly. A minimal calorie-free fluid input of 2 l/day was maintained. A polyvitamin preparation lacking vitamin D was given daily, potassium was administered whenever there was a tendency for lowering of serum potassium. Allopurinol (300 mg/day) which is known to leave iodine metabolism unchanged (*Rosenkrantz et al.* 1968), was administered orally, whenever the uric acid level rose above 12 mg/100 ml. Some patients received colloidal aluminium phosphate. Blood samples were drawn between 8 and 9 a.m. at intervals indicated in Figs. 1 and 2, and before breakfast during the re-alimentation period.

### *Laboratory methods*

Triiodothyronine,  $T_3$  (*Horn et al.* 1975), reverse triiodothyronine,  $rT_3$  (*Meinhold et al.* 1975), thyroxine binding globulin, TBG (*Horn et al.* 1977), thyrotrophin (*Erhardt et al.* 1973), cortisol (*Horn et al.* 1975), corticosteroid binding globulin, CBG (*Bernutz et al.* 1978), parathyrin, PTH (*Wood et al.* 1978), growth hormone and prolactin (*von Werder* 1975) were determined by published radioimmunoassay (RIA) procedures. Thyroxine determinations, using competitive protein binding assay (CPBA), and  $T_3$ -uptake tests,  $T_3U$ , were performed as published (*Horn et al.* 1975). Transferrin,  $\alpha_2$ -haptoglobin and complement C<sub>3</sub> were determined by radial immunodiffusion after *Mancini et al.* (1965) and *Lamerz et al.* (1973). Free fatty acids, FFA, were analysed by a modification (*Dieterle et al.* 1968) of the colorimetric assay (*Duncombe* 1963).

### *Statistical evaluation*

Student's *t*-test was used for the comparison of pre-fasting levels of obese patients and of controls. Student's non-paired *t*-test may however not be used for the evaluation of sequential changes when more than two sampling times are involved. The sequential data during total fasting and re-alimentation are certainly not independent. Therefore, the regression of the measured values against the time and also the linearity (one way analysis of variance) were calculated (*Sachs* 1972). The significance of observed alterations could then be calculated from the correlation coefficient *r* and from the number of determinations *N*. Both, the fasting and the re-alimentation were separated into two periods in order to allow for better description of the kinetics of the observed alterations: Fasting periods I (day 1–15) and II (day 15–end); re-alimentation periods I (day 1–6) and II (day 6–30).




Fig. 1.

Triiodothyronine ( $T_3$ -RIA),  $rT_3$ , thyroxine binding globulin,  $T_3$ /TBG ratio, and free fatty acids before and during fasting and re-alimentation of obese patients.

Superimposed normal means  $\pm 2$  standard deviations of all measured parameters correspond to the following data:

$T_3$ -RIA:  $116 \pm 36$  ng/100 ml;  $rT_3$ :  $0.207 \pm 0.184$  ng/ml; TBG:  $2.0 \pm 0.8$  ml/100 ml;  
 $T_3$ /TBG:  $58 \pm 36$ , FFA:  $480 \pm 250$   $\mu$ Eq/l.

## RESULTS

### Triiodothyronine ( $T_3$ )

The initial  $T_3$  levels of the obese patients ( $N = 18$ ) of  $141 \pm 21$  ng/100 ml (mean  $\pm$  SD) were within the normal range but significantly ( $P < 0.001$ ) above the mean (Horn 1976) of healthy normal weight controls ( $N = 58$ ) of  $116 \pm 18$  ng/100 ml (Horn 1976). A rapid decline of the  $T_3$  levels was observed during the first 2 weeks of total fasting (Fig. 1, Table 1). The decrease was linear and significant ( $r = -0.6379$ ;  $P < 0.001$ ,  $N = 58$ ). A linear increase was observed during the second fasting period, i.e. after the 15th day ( $r = +0.3781$ ;  $P < 0.001$ ,  $N = 50$ ). A further increase of the  $T_3$  levels was observed during the re-alimentation period, which was linear and significant during the first re-alimentation period ( $r = +0.2579$ ;  $P < 0.05$ ,  $N = 62$ ) and non-linear but significant after the 6th day of re-alimentation ( $r = +0.4138$ ;  $P < 0.05$ ,  $n = 27$ ).

### Reverse $T_3$ ( $rT_3$ )

The sequential  $rT_3$  levels were determined in only 5 patients. The initial  $rT_3$  level of these patients of  $0.22 \pm 0.06$  ng/ml (mean  $\pm$  SD) was within the

Table 1.

Changes in the serum levels of triiodothyronine ( $T_3$ ), ( $rT_3$ ), thyroxine ( $T_4$ ), thyroxine binding globulin (TBG),  $T_4$ /TBG ratio,  $T_3$ /TBG ratio,  $T_3$ -uptake, free thyroxine index, free fatty acids and basal thyrotrophin, respectively TSH increase 30 min after 200  $\mu$ g TRH iv, before and during fasting and re-alimentation of obese patients (mean  $\pm$  sd).

	Total fasting			Re-alimentation		
	before	7.-15. day	25.-30. day	before	5.-6. day	15.-30. day
$T_3$ ng/100 ml	141 $\pm$ 21	77 $\pm$ 14	86 $\pm$ 18	89 $\pm$ 24	107 $\pm$ 22	144 $\pm$ 36
$rT_3$ ng/ml	0.22 $\pm$ 0.06	0.38 $\pm$ 0.15	0.27 $\pm$ 0.10	0.24 $\pm$ 0.03	0.18 $\pm$ 0.02	0.20 $\pm$ 0.04
$T_4$ $\mu$ g/100 ml	8.3 $\pm$ 2.4	8.1 $\pm$ 2.3	7.2 $\pm$ 1.7	7.4 $\pm$ 1.5	7.4 $\pm$ 1.2	8.1 $\pm$ 2.1
TBG mg/100 ml	2.6 $\pm$ 0.5	2.2 $\pm$ 0.3	1.9 $\pm$ 0.2	2.0 $\pm$ 0.2	1.9 $\pm$ 0.3	2.4 $\pm$ 0.6
$T_4$ /TBG	3.20 $\pm$ 0.94	3.76 $\pm$ 1.09	3.70 $\pm$ 0.90	3.78 $\pm$ 0.9	3.86 $\pm$ 0.93	3.72 $\pm$ 1.18
$T_3$ /TBG	58.1 $\pm$ 17.8	35.8 $\pm$ 6.0	45.0 $\pm$ 10.2	46.2 $\pm$ 12.4	55.3 $\pm$ 12.9	60.7 $\pm$ 15.0
$RT_3U$ %	31.3 $\pm$ 4.6	37.8 $\pm$ 5.0	38.7 $\pm$ 4.8	38.1 $\pm$ 5.9	36.2 $\pm$ 6.5	33.8 $\pm$ 7.0
$fT_4$ -I	2.56 $\pm$ 0.66	3.04 $\pm$ 0.91	2.86 $\pm$ 0.64	2.80 $\pm$ 0.67	2.65 $\pm$ 0.57	2.64 $\pm$ 0.73
FFA $\mu$ Eq/l	591 $\pm$ 108	1395 $\pm$ 514	1594 $\pm$ 636	1288 $\pm$ 530	832 $\pm$ 327	688 $\pm$ 207
TSH basal $\mu$ U/ml	1.3 $\pm$ 0.7	1.4 $\pm$ 0.5				1.4 $\pm$ 0.5
$\Delta TSH_{30min}$ $\mu$ U/ml	6.8 $\pm$ 3.9	5.6 $\pm$ 2.1				9.1 $\pm$ 4.7

normal range of 0.023–0.391 ng/ml. A significant increase of this metabolite (Fig. 1, Table 1) was observed during the first fasting period ( $r = +0.5683$ ;  $P < 0.05$ ,  $N = 14$ ). A mirror image decline in  $rT_3$  levels was seen during the second fasting period when compared with the  $T_3$  levels. A further significant decrease of  $rT_3$  was observed during the first re-alimentation period ( $r = -0.5955$ ;  $P < 0.01$ ,  $N = 20$ ).

#### *Thyroxine ( $T_4$ )*

The initial  $T_4$  levels (Table 1) in obese patients of  $8.3 \pm 2.4$   $\mu\text{g}/100$  ml were significantly higher than the mean value of age-matched normal weight controls (Horn 1976; Horn *et al.* 1977) of  $6.7 \pm 1.3$   $\mu\text{g}/100$  ml ( $P < 0.01$ ). There were no significant changes of the  $T_4$  levels neither during fasting nor during re-alimentation.

#### *Thyroxine binding globulin (TBG)*

The initial TBG levels (Fig. 1, Table 1) of obese patients of  $2.6 \pm 0.6$  mg/100 ml were significantly higher than the mean of age-matched normal weight controls of  $2.0 \pm 0.4$  mg/100 ml ( $P < 0.001$ ). The TBG levels decreased significantly and linearly ( $r = -0.3957$ ;  $P < 0.001$ ,  $N = 56$ ) during the first fasting period. No further change of the TBG level was observed during the second fasting period. However, a significant increase of the mean TBG level was observed during the re-alimentation period ( $r = +0.3049$ ;  $P < 0.01$ ,  $N = 80$ ).

#### *$T_4$ /TBG ratio*

Before the fasting, the mean  $T_4$ /TBG ratio of obese patients of  $3.20 \pm 0.94$  ( $\mu\text{g}/\text{mg}$ ; equivalent to a molar ratio of 0.249) was practically identical with the mean of age-matched normal weight controls (Horn *et al.* 1977) of  $3.17 \pm 0.88$ . A significant and linear increase of the  $T_4$ /TBG ratio ( $r = +0.2567$ ;  $P < 0.01$ ,  $N = 102$ ) was observed during the complete fasting period, whereas the  $T_4$ /TBG ratio remained elevated during re-alimentation.

#### *$T_3$ /TBG ratio*

The  $T_3$ /TBG ratio decreased from an initial value of  $58 \pm 18$  (ng/mg, which is equivalent to a molar ratio of 0.021) significantly and linearly to  $36 \pm 6$  ( $r = -0.4904$ ;  $P < 0.001$ ,  $N = 56$ ) during the first fasting period (Fig. 1, Table 1). During the second fasting period, however, the  $T_3$ /TBG ratio rose already significantly and linearly ( $r = +0.3429$ ;  $P < 0.05$ ,  $N = 50$ ). There was a further significant but non-linear increase of the  $T_3$ /TBG ratio during re-alimentation ( $r = -0.3860$ ;  $P < 0.001$ ,  $N = 74$ ).




Fig. 2.

$T_3$ -uptake ( $RT_3U$ ), thyroxine binding globulin, thyroxine, free fatty acids, and free thyroxine index before and during fasting and re-alimentation of obese patients.

Superimposed normal means  $\pm 2$  standard deviations of all measured parameters correspond to the following data:

$RT_3U$ :  $37 \pm 5\%$ ;  $TBG$ :  $2.0 \pm 0.8$  mg/100 ml;  $T_4$ :  $6.7 \pm 2.6$   $\mu$ g/100 ml;  $FFA$ :  $480 \pm 250$   $\mu$ Eq./l,  $fT_4$ -index:  $2.9 \pm 0.9$ .

#### $T_3$ -uptake test ( $RT_3U = resin T_3$ uptake)

The  $T_3$ -uptake of the obese patients (Fig. 2, Table 1) of  $31.3 \pm 4.6\%$  was initially just below the normal range of 32–42% (Horn *et al.* 1975) and thus significantly lower (Scriba *et al.* 1967) than in healthy normal weight controls ( $P < 0.001$ ). There was a significant and linear increase of the  $T_3$ -uptake ( $r = +0.4202$ ;  $P < 0.01$ ,  $N = 55$ ) during the first 15 days of fasting. The decrease of the  $T_3$ -uptake during re-alimentation was again linear and significant ( $r = -0.3021$ ;  $P < 0.001$ ,  $N = 80$ ).

#### Free thyroxine index ( $fT_4$ -index)

The  $fT_4$ -index ( $T_4 \times RT_3U$ ) was initially  $2.56 \pm 0.66$  in the obese patients and thus significantly lower than in healthy normal weight controls (Fig. 2, Table 1). A slight increment to  $3.04 \pm 0.91$  was observed during the first fasting period ( $r = +0.2346$ ;  $P < 0.05$ ,  $N = 55$ ) with a subsequent decrease toward the initial value.

Table 2.

Changes in serum levels of the glycoproteins corticosteroid binding globulin, transferrin,  $\alpha_2$ -haptoglobin and complement C'3 ( $\beta_1$ A-globulin), of cortisol and of the cortisol/CBG ratio before and during fasting and re-alimentation of obese patients (mean  $\pm$  SD).

	Total fasting			Re-alimentation		
	before	7.-15. day	25.-30. day	before	5.-6. day	15.-30. day
CBG mg/100 ml	4.0 $\pm$ 1.1	4.1 $\pm$ 1.4	3.7 $\pm$ 0.9	3.5 $\pm$ 0.8	3.9 $\pm$ 1.5	3.5 $\pm$ 1.0
Cortisol $\mu$ g/100 ml	19.0 $\pm$ 9.4	19.5 $\pm$ 9.5	18.0 $\pm$ 10.8	19.7 $\pm$ 9.8	17.9 $\pm$ 8.1	11.8 $\pm$ 4.5
Cortisol/CBG ratio	5.13 $\pm$ 2.79	5.95 $\pm$ 4.68	5.46 $\pm$ 4.00	5.83 $\pm$ 3.10	5.17 $\pm$ 2.19	3.41 $\pm$ 1.11
Transferrin mg/100 ml	293 $\pm$ 47	238 $\pm$ 67	221 $\pm$ 39	212 $\pm$ 39	219 $\pm$ 41	249 $\pm$ 46
$\alpha_2$ -haptoglobin mg/100 ml	250 $\pm$ 138	131 $\pm$ 55	126 $\pm$ 69	155 $\pm$ 90	178 $\pm$ 111	228 $\pm$ 156
Complement C'3 mg/100 ml	131 $\pm$ 14	101 $\pm$ 24	97 $\pm$ 37	100 $\pm$ 32	104 $\pm$ 38	109 $\pm$ 27

### *TSH levels before and after TRH stimulation tests*

The mean basal TSH levels of the obese patients (Table 1) and the TSH increments observed after TRH stimulation were within the normal range. Both values, however, measured in 16 patients before the initiation of the fasting, were significantly lower ( $P < 0.0025$ ) than in healthy normal weight controls (Erhardt *et al.* 1973). The TSH increment of  $5.6 \pm 2.1 \mu\text{U/ml}$ , measured in the obese patients after 2 weeks of fasting, was not significantly lower than the initial value. However, the TSH increment after 2 weeks of re-alimentation (Table 1) was significantly higher ( $P < 0.005$ ) than during fasting.

### *Free fatty acids (FFA)*

The free fatty acids (Fig. 1, Table 1) were elevated throughout the complete fasting period. A sharp linear and significant FFA increase was observed during the first fasting period ( $r = +0.6933$ ;  $P < 0.001$ ,  $N = 54$ ). A linear and significant decrease of the FFA was observed during the first 6 days of re-alimentation ( $r = -0.3545$ ;  $P < 0.01$ ,  $N = 61$ ).

### *Cortisol*

The obese patients had cortisol levels of  $19.0 \pm 9.4 \mu\text{g}/100 \text{ ml}$  (Table 2). The mean cortisol level of the obese patients was found at the upper limit of the normal range (Horn *et al.* 1975) and was significantly higher than the mean of healthy normal weight controls of  $11.1 \pm 3.7 \mu\text{g}/100 \text{ ml}$  ( $P < 0.01$ ). Cortisol levels remained constant during fasting but a significant decrease to  $11.8 \pm 4.5 \mu\text{g}/100 \text{ ml}$  was seen during re-alimentation ( $r = -0.2450$ ;  $P < 0.05$ ,  $N = 77$ ).

### *Corticosteroid-binding globulin (CBG)*

The mean CBG levels of the obese patients (Table 2) were initially  $4.0 \pm 1.1 \text{ mg}/100 \text{ ml}$  ( $N = 18$ ) and thus significantly ( $P < 0.005$ ) higher than the mean of age-matched normal weight controls of  $3.4 \pm 0.5 \text{ mg}/100 \text{ ml}$  ( $N = 40$ ). The CBG levels remained constant during the first fasting period and showed a non-significant decline during the second fasting period ( $r = -0.2404$ ;  $P < 0.1$ ,  $N = 50$ ). Likewise, there were no significant alterations of the CBG levels during re-alimentation.

### *Cortisol/CBG ratio*

The cortisol/CBG ratio of the obese patients was initially  $5.13 \pm 2.79$  and remained constant during the complete fasting period (Table 2). A decrease was observed at the end of the re-alimentation period which paralleled the decline of the cortisol levels ( $r = -0.2628$ ;  $P < 0.005$ ,  $N = 76$ ).

### *Transferrin*

The initial transferrin levels of the obese patients of  $293 \pm 47$  mg/100 ml were not significantly different from the mean normal weight controls (*Fateh-Moghadam et al.* 1977) of  $295 \pm 95$  mg/100 ml (Table 2). A significant and linear decrease was observed during the complete fasting period ( $r = -0.6270$ ;  $P < 0.001$ ,  $N = 98$ ) with a minimum of  $212 \pm 35$  mg/100 ml. The transferrin levels rose during re-alimentation linearly and significantly to  $249 \pm 46$  mg/100 ml ( $r = +0.3655$ ;  $P < 0.001$ ,  $N = 78$ ).

### *$\alpha_2$ -haptoglobin*

The  $\alpha_2$ -haptoglobin levels of obese patients were initially  $250 \pm 138$  mg/100 ml and thus above the normal range of 25–220 mg/100 ml (*Fateh-Moghadam et al.* 1977). The  $\alpha_2$ -haptoglobin levels decreased linearly and significantly during the first fasting period (Table 2) to a minimum of  $126 \pm 69$  mg/100 ml ( $r = -0.3341$ ;  $P < 0.05$ ,  $N = 51$ ). An increase was already observed during the second fasting period ( $r = +0.3375$ ;  $P < 0.005$ ,  $N = 50$ ) followed by a further linear and significant increase during the re-alimentation period ( $r = +0.3162$ ;  $P < 0.01$ ,  $N = 78$ ).

### *Complement C'3 ( $\beta_1A$ -globulin)*

The initial complement C'3 levels of the obese patients ( $131 \pm 13.6$  mg/100 ml) were higher as compared to normal weight controls ( $108 \pm 15$  mg/100 ml) (*Fateh-Moghadam et al.* 1977). There was a significant decrease (Table 2) during fasting ( $r = -0.3489$ ;  $P < 0.001$ ,  $N = 98$ ), whereas during subsequent re-alimentation, the complement C'3 levels rose linearly, but not significantly, to  $109 \pm 27$  mg/100 ml ( $r = +0.1978$ ;  $P < 0.1$ ,  $N = 78$ ). The complement C'3 level did not reach the initial value during the observation period, however, the mean of normal weight controls was reached.

### *Parathyrin (PTH)*

The initial mean PTH levels of obese patients were with  $0.35 \pm 0.31$  ng/100 ml within the normal range of 0.2–1.0 ng/ml (*Wood et al.* 1978). No significant alterations were observed during fasting and re-alimentation. However, 47 of a total of 164 sera obtained for PTH determination showed a PTH level below the limit of detection of 0.2 ng/ml (28.6%). The correct calcium balance could not be calculated in this study, but the calcium intake, chiefly through mineral water, was estimated to be 200–300 mg/day.

### *Growth hormone and prolactin*

No significant alterations of the growth hormone and prolactin levels were observed during fasting and during re-alimentation, either in male or in female patients.

## DISCUSSION

### *Obese patients before fasting*

Early observations (Scriba *et al.* 1967) have shown that the protein bound iodine (PB<sup>127</sup>I) and particularly the T<sub>3</sub>-uptake were significantly lower in obese patients than in normal weight controls, although the mean values of both were within the normal ranges. The possibility of a tendency towards thyroid hormone deficiency in obesity was discussed on the basis of these studies. However, the direct determination of T<sub>3</sub> and T<sub>4</sub>, and of TSH levels before and after TRH stimulation, showed that patients with alimentary obesity have higher mean T<sub>3</sub> levels than normal weight controls (Bray *et al.* 1976; Hofmann *et al.* 1974), and that the TSH levels before and after TRH stimulation are not elevated. It was concluded from the latter studies, that obese patients are euthyroid and that at least primary hypothyroidism can be excluded for this condition.

This study shows that the mean values of T<sub>4</sub>, T<sub>3</sub> and TBG in obese patients are elevated but within the normal range (Figs. 1 and 2) as compared with normal weight controls. The normal T<sub>4</sub>/TBG ratio and the normal TSH levels of these patients (Table 1) speak against any primary hypothyroidism in these patients.

Some serum proteins are known to be elevated in non-fasted obese patients, e.g. albumin and pseudocholinesterase (Fateh-Moghadam *et al.* 1977). In accordance with earlier observations (Fateh-Moghadam *et al.* 1977), the patients of this study were found to have elevated mean values for  $\alpha_2$ -haptoglobin and complement C'3. Moreover, this is the first demonstration of elevated TBG and CBG levels by direct measurement. Nothing appears to be known about the regulation of the different serum proteins in hyperalimentation of different dietary composition.

### *Effects of total fasting*

The study confirms the rapid decline of T<sub>3</sub> and the mirror image increase of rT<sub>3</sub> during fasting, as published by other investigators (Balsam & Ingbar 1977; Carlson *et al.* 1977; Croxson *et al.* 1977; Merimee & Fineberg 1976; Palmblad *et al.* 1977; Portnay *et al.* 1974; Vagenakis *et al.* 1975, 1977). This "shift" of the peripheral monodeiodination of T<sub>4</sub> from the metabolically active triiodothyronine to the inactive rT<sub>3</sub> can be interpreted as adaptation of metabolism to the reduction of energy provision from calorie-intake. The mechanism of this alteration of the hormone metabolism remains unknown (Balsam & Ingbar 1977; Chopra 1978; Palmblad *et al.* 1977). The obvious kinetic parallelism of the increases of the FFA and rT<sub>3</sub> levels and their inverse relation to T<sub>3</sub> raise the question of the regulatory effect of FFA on the monodeiodination of T<sub>4</sub>. It should be noted in addition, that recently a decrease of the hepatic T<sub>3</sub> receptor binding capacity during fasting was shown (Schussler & Orlando 1978).

The thyroxine levels of obese patients remained constant during total fasting in accordance with the literature. (*Merimee & Fineberg 1976; Palmblad et al. 1977; Portnay et al. 1974*). Here, the long half-life of  $T_4$  has to be taken into consideration.

A decrease of thyroxine binding capacity (*Schatz et al. 1967*) was observed in serum of fasting obese patients, and low TBG levels were reported in protein calorie malnutrition (*Rastogi et al. 1974; Chopra & Smith 1975*). This study has shown, by direct radioimmunoassay (*Horn et al. 1977*), that the TBG levels decrease during the first 2 weeks of total fasting. Interestingly similar kinetics were observed for the decrease of complement C'3,  $\alpha_2$ -haptoglobin and transferrin during fasting. Corticosteroid binding globulin and likewise albumin (*Fateh-Moghadam et al. 1977*), however, remained constant throughout the complete fasting period. It remains an open problem, as to why only certain serum proteins decrease rapidly during total fasting. This decrease appears to include mainly those serum proteins, which are elevated in obese patients before fasting when compared with normal weight controls. As the mean of the serum proteins does not fall essentially below the respective normal values with the duration of total fasting applied in this study, it appears unlikely that the patients are in any danger, for example of becoming deficient in immunoglobulins.

The decrease of the specific transport globulins of thyroid hormones explains only partially the known increment in  $T_3$ -uptake (*Schatz et al. 1967; Scriba & Hofmann 1976*) and decrease of total  $T_3$ . Comparing the kinetics of the TBG decrease and of the increase of  $T_3$ -uptake (Fig. 2) it can be seen that the increment of  $T_3$ -uptake is more rapid. The displacement of thyroid hormones from TBG by the FFA increase has been suggested (*Hollander et al. 1967*) as one explanation for the phenomenon. Further, total  $T_3$  decreases more rapidly and intensively than TBG (Fig. 1), explaining the depression of the  $T_3$ /TBG ratio during the first fasting period. The  $T_3$ /TBG ratio increases already during the second fasting period in parallel to the  $T_3$  levels. These results show that the most evident metabolic alterations occur within the first 2 weeks of total fasting.

An increase of the  $T_4$ /TBG ratio was observed in obese patients after 2 weeks of total fasting in contrast to the decrease of the  $T_3$ /TBG ratio when compared with the initial values. This leads to the important question as to whether obese patients are indeed euthyroid throughout the complete fasting period, particularly with respect to the known decrease of daily weight loss with longer duration of the fasting (*Ditschuneit 1976*). If one accepts the TSH response to TRH stimulation as the most sensitive parameter for the thyroid hormone status of a patient, the results of this study exclude any primary hypothyroidism. In accordance with other investigators (*Carlson et al. 1977; Croxson et al. 1977; Palmblad et al. 1977; Portnay et al. 1974; Vinik et al. 1975*), no in-

creased TSH response was observed but rather a tendency to a slightly decreased TSH increment after TRH stimulation during fasting. The possibility should be kept in mind, that these TSH levels are inadequately low. Conversely, one should realise the possibility of an alteration of hypothalamic or pituitary functions during total fasting (*Carlson et al. 1977*). Secondary endocrine disturbances of this type have been repeatedly documented for patients with anorexia nervosa (*Travaglini et al. 1976; Vigersky et al. 1976*); thus some degree of thyroid hormone deficiency due to hypothalamic dysfunction cannot be excluded with certainty on the basis of current data. The latter possibility could serve as a vague rational basis for the acceleration of the weight loss of fasting obese patients, when, for example, 60  $\mu\text{g}$   $\text{T}_3$  per day are given additionally (*Hofmann et al. 1974; Scriba & Hofmann 1976*).

### *Re-alimentation*

A rapid normalisation of the free fatty acids was observed during re-alimentation with a low caloric diet, representing a normalisation of the stimulated lipolysis.  $\text{T}_3$  levels were normalised within the first days of re-alimentation and reached the initially elevated mean values of obese patients during the second period of re-alimentation. Recently it was shown that glucose given orally but not intravenously normalises  $\text{T}_3$  levels after 48 h fasting (*Westgren et al. 1977*). Obviously, the peripheral thyroid hormone metabolism was rapidly normalised during re-alimentation.

The increase of the TBG levels was somewhat slower, resulting in an still elevated  $\text{T}_3/\text{TBG}$  ratio at the end of the observed period of re-alimentation. The  $\text{T}_4/\text{TBG}$  ratio was increased during the complete re-alimentation period when compared with the initial value. In spite of this, the TSH response to TRH stimulation was higher at the end of the re-alimentation than during fasting (Table 1). The increasing TBG levels probably bind more  $\text{T}_4$ , which can be supplied by the thyroid only at the cost of increased thyrotrophic stimulation.

Transferrin,  $\alpha_2$ -haptoglobin and complement C'3 increase during re-alimentation. None of these serum proteins, however, reached the initially elevated levels observed in obese patients until the end of the observed period of re-alimentation. This finding shows that there is no persisting deficiency of serum proteins after total fasting.

### ACKNOWLEDGMENTS

The authors are indebted to Dr. Harald Meinhold, Berling, for determining the reverse  $\text{T}_3$  levels by radioimmunoassay.

These studies were supported by the Deutsche Forschungsgemeinschaft (SFB 51) and by the Federico Foundation, Munich.

## REFERENCES

- Balsam A. & Ingbar S. H.*: Ann. Endocr. (Paris) 38 (1977) 33A.
- Bernutz C., Horn K. & Pickardt C. R.*: Acta endocr. (Kbh.) Suppl. 215 (1978) 25.
- Bray G. A., Fisher D. A. & Chopra I. J.*: Lancet 1 (1976) 1206.
- Carlson H. E., Drenick E. J., Chopra I. J. & Hershman J. M.*: J. clin. Endocr. 45 (1977) 707.
- Chopra I. J.*: Science 199 (1978) 904.
- Chopra I. J. & Smith S. R.*: J. clin. Endocr. 40 (1975) 221.
- Crosson M. S., Hall T. D., Kletzky O. A., Jaramillo J. E. & Nicoloff J. T.*: J. clin. Endocr. 45 (1977) 560.
- Dieterle P., Wülfert-Heldrich C., Henner J. & Schwarz K.*: Z. klin. Chem. klin. Biochem. 6 (1968) 153.
- Ditschuneit H.*: Internist 17 (1976) 622.
- Duncombe W.*: Biochem. J. 88 (1963) 7.
- Erhardt F. W., Marschner I., Pickardt C. R. & Scriba P. C.*: Z. klin. Chem. klin. Biochem. 11 (1973) 381.
- Fateh-Moghadam A., Schwandt P., Sandel P., Vogt W. & Kling S.*: Klin. Wschr. 55 (1977) 525.
- Hofmann G. G., Strohmeier E., Pickardt C. R., Horn K. & Scriba P. C.*: Verh. dtsch. Ges. inn. Med. 80 (1974) 1346.
- Hollander S. C., Scott R. L., Burgess J. A., Rabinowitz D., Merimee T. J. & Oppenheimer J. H.*: J. clin. Endocr. 27 (1967) 1219.
- Horn K.*: Trijodthyronin ( $T_3$ ): Zur Bestimmung und pathophysiologischen Bedeutung. Urban und Schwarzenberg, München, Berlin, Wien (1976) p. 1-146.
- Horn K., Henner J., Müller O. A. & Scriba P. C.*: Z. klin. Chem. klin. Biochem. 13 (1975) 173.
- Horn K., Kubiczek T., Pickardt C. R. & Scriba P. C.*: Klin. Wschr. 55 (1977) 881.
- Lamerz R., Fateh-Moghadam A. & Knedel M.*: Z. klin. Chem. klin. Biochem. 11 (1973) 491.
- Mancini G., Carbonara A. O. & Heremans J. F.*: Immunochemistry 2 (1965) 235.
- Meinhold H., Wenzel K. W. & Schürnbrand P.*: Z. klin. Chem. klin. Biochem. 13 (1975) 571.
- Merimee T. J. & Fineberg E. S.*: Metabolism 25 (1976) 79.
- Palmblad J., Levi L., Burger A., Melander A., Westgren U., von Schenck H. & Skude G.*: Acta med. scand. 201 (1977) 15.
- Portnay G. I., O'Brian J. T., Bush J., Vagenakis A. G., Azizi F., Arky R. A., Ingbar S. H. & Braverman L. E.*: J. clin. Endocr. 39 (1974) 191.
- Premachandra B. N., Perlstein I. B. & Blumenthal H. T.*: J. clin. Endocr. 30 (1970) 752.
- Rastogi G. K., Sawhney R. C., Panda N. C. & Tripathy B. B.*: Horm. Metab. Res. 6 (1974) 528.
- Rosenkrantz M., Schaeppi U., Fabry A., Davis R. D. & Cooney D. A.*: Biochem. Pharmacol. 17 (1968) 2357.
- Sachs L.*: Statistische Auswertungsmethoden, 3. Aufl. Springer, Berlin, Heidelberg, New York (1972) p. 1-545.
- Schatz D. L., Sheppard R. H., Palter H. C. & Jaffri M. H.*: Metabolism 16 (1967) 1075.
- Schussler G. C. & Orlando J.*: Science 199 (1978) 686.
- Scriba P. C., Bauer M., Emmert D., Hofmann G. G., Horn K. & Pickardt C. R.*: Acta endocr. (Kbh.) Suppl. 212 (1977) 85.
- Scriba P. C. & Hofmann G. G.*: Verh. dtsch. Ges. inn. Med. 82 (1976) 1398.

- Scriba P. C., Richter J., Horn K., Beckebans J. & Schwarz K.: *Klin. Wschr.* 45 (1967) 323.
- Travaglini P., Beck-Peccoz P., Ferrari C., Ambrosi B., Paracchi A., Severgnini A., Spada A. & Faglia G.: *Acta endocr. (Kbh.)* 81 (1976) 252.
- Vagenakis A. G., Burger A., Portnay G. I., Rudolph M., O'Brian J. T., Azizi F., Arky R. A., Nicod P., Ingbar S H. & Braverman L. E.: *J. clin. Endocr.* 41 (1975) 191.
- Vagenakis A. G., Portnay G. I., O'Brian J. T., Rudolph M., Arky R. A., Ingbar S. H & Braverman L. E.: *J. clin. Endocr.* 45 (1977) 1305.
- Vigersky R. A., Loriaux D. L., Andersen A. E., Mecklenburg R. S. & Vaitukaitis J. L.: *J. clin. Endocr.* 43 (1976) 893.
- Vinik A. J., Kalk W. J., McLaren H., Hendricks S. & Pimstone B. L.: *J. clin. Endocr.* 40 (1975) 509.
- von Werder K.: *Wachstumshormone und Prolactin-Sekretion des Menschen.* Urban und Schwarzenberg, München, Berlin, Wien (1975) p. 1-244.
- Westgren U., Ahrén B., Burger A. & Melander A.: *Acta endocr. (Kbh.)* 85 (1977) 526.
- Wood W. G., Marschner I. & Scriba P. C.: *Z. analyt. Chem.* 290 (1978) 170.

Received on December 20th, 1979.